Hemophilia carrier's awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d'Ivoire (Ivory Coast).
Carrier of hemophilia
Data collection
Developing countries
Ivory Coast
WFH twinning program
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
08
09
2018
accepted:
21
01
2019
entrez:
3
2
2019
pubmed:
3
2
2019
medline:
20
4
2019
Statut:
epublish
Résumé
Little data is available on awareness of hemophilia carrier condition or associated bleeding risk and management in Sub-Saharan African countries. This study sought to identify hemophilia carriers in Côte d'Ivoire in order to collect data on demographics, bleeding phenotype, and laboratory results. Another purpose was to provide Ivorian hemophilia carriers with counseling on their risk of bleeding and of having children with hemophilia. A 12-month prospective study was conducted involving Ivorian hemophilia carriers recruited trough pedigree analysis pertaining to 81 hemophilia patients followed-up at the Yopougon Hemophilia Treatment Center in Abidjan. They were assessed using in-depth interviews, pedigree analysis, and laboratory testing. Sixty-one subjects comprising 27 obligate and 34 possible carriers were recruited. None had previously been assessed, with 64% unaware of their carrier status despite a familial history of hemophilia in 69%. The most frequently reported bleeding symptom was menorrhagia (31%). Prolonged bleeding was reported after vaginal delivery in 19.6%, post-surgery in 4.9%, and post-dental extraction in 4.9%. Only one carrier was treated with tranexamic acid, with no other hemostatic therapy recorded. The median (range) clotting FVIII was 0.85 IU/mL (0.24-1.90 IU/mL) and FIX 0.60 IU/mL (0.42-1.76 IU/mL) in hemophilia A and B carriers, respectively. HA carriers had a FVIII < 0.5 IU/mL in 12.5%. This study highlights the need of implementing care for hemophilia carriers in developing countries, and the high value of pedigree analysis for carrier identification, along with the relevance of diagnosis, treatment, and education of carriers, families, and caregivers.
Sections du résumé
BACKGROUND
Little data is available on awareness of hemophilia carrier condition or associated bleeding risk and management in Sub-Saharan African countries. This study sought to identify hemophilia carriers in Côte d'Ivoire in order to collect data on demographics, bleeding phenotype, and laboratory results. Another purpose was to provide Ivorian hemophilia carriers with counseling on their risk of bleeding and of having children with hemophilia. A 12-month prospective study was conducted involving Ivorian hemophilia carriers recruited trough pedigree analysis pertaining to 81 hemophilia patients followed-up at the Yopougon Hemophilia Treatment Center in Abidjan. They were assessed using in-depth interviews, pedigree analysis, and laboratory testing.
RESULTS
Sixty-one subjects comprising 27 obligate and 34 possible carriers were recruited. None had previously been assessed, with 64% unaware of their carrier status despite a familial history of hemophilia in 69%. The most frequently reported bleeding symptom was menorrhagia (31%). Prolonged bleeding was reported after vaginal delivery in 19.6%, post-surgery in 4.9%, and post-dental extraction in 4.9%. Only one carrier was treated with tranexamic acid, with no other hemostatic therapy recorded. The median (range) clotting FVIII was 0.85 IU/mL (0.24-1.90 IU/mL) and FIX 0.60 IU/mL (0.42-1.76 IU/mL) in hemophilia A and B carriers, respectively. HA carriers had a FVIII < 0.5 IU/mL in 12.5%.
CONCLUSIONS
This study highlights the need of implementing care for hemophilia carriers in developing countries, and the high value of pedigree analysis for carrier identification, along with the relevance of diagnosis, treatment, and education of carriers, families, and caregivers.
Identifiants
pubmed: 30709356
doi: 10.1186/s13023-019-1005-9
pii: 10.1186/s13023-019-1005-9
pmc: PMC6359866
doi:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Factor VIII
9001-27-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Références
Haemophilia. 2011 Mar;17(2):246-51
pubmed: 21118332
J Genet Couns. 2015 Dec;24(6):978-86
pubmed: 25828422
Am J Hum Genet. 1962 Jun;14:135-48
pubmed: 14467629
Haemophilia. 2018 May;24 Suppl 6:29-36
pubmed: 29878651
Haemophilia. 2017 May;23(3):e225-e227
pubmed: 28306216
Blood. 1987 May;69(5):1539-41
pubmed: 2882794
Br J Haematol. 1997 Jun;97(3):558-60
pubmed: 9207400
Haemophilia. 2010 Jan;16(1):20-32
pubmed: 19845775
BMC Hematol. 2017 Apr 24;17:8
pubmed: 28451435
Haemophilia. 1998 Jul;4(4):341-5
pubmed: 9873752
Br J Haematol. 1975 Aug;30(4):447-56
pubmed: 1103952
Haemophilia. 2002 Jan;8(1):51-5
pubmed: 11886465
N Engl J Med. 2001 Jun 7;344(23):1773-9
pubmed: 11396445
Blood Coagul Fibrinolysis. 2017 Dec;28(8):642-645
pubmed: 28731872
Br J Haematol. 2015 Jul;170(2):223-8
pubmed: 25832012
Blood. 2006 Jul 1;108(1):52-6
pubmed: 16551972
Haemophilia. 2004 Sep;10(5):560-4
pubmed: 15357784
Haemophilia. 2008 Jul;14 Suppl 3:181-7
pubmed: 18510540
Haemophilia. 2010 Jan;16(1):111-7
pubmed: 19758307
Haemophilia. 2002 Sep;8(5):680-4
pubmed: 12199679
Ann Hematol. 1992 Jan;64(1):2-11
pubmed: 1739755